EN 002
Alternative Names: EN-002; In vivo HER2 targeting CAR cell therapy - Ensoma; Lineage-restricted multiplexed CAR-M, CAR-NK, CAR-T cell therapy - EnsomaLatest Information Update: 25 May 2026
At a glance
- Originator Ensoma
- Class Antineoplastics; Gene therapies; Immunotherapies; Viruses
- Mechanism of Action Immunologic cytotoxicity; Macrophage replacements; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours